Nanobiotix SA
NBTXHealthcare|Biotechnology|France
$39.95
+1.12 (+2.88%)
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07224152 NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer | Locally-Advanced Non-Small Cell Lung Cancer | P1P2 | Recruiting | 40 | Open-label | NBTXR3 |
| NCT03589339 NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | Radiotherapy, Immunotherapy | P1 | Active | 145 | Open-label | NBTXR3, Nivolumab, Pembrolizumab |
| NCT02379845 NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | Adult Soft Tissue Sarcoma | P2P3 | Completed | 180 | RCT, Open-label | — |
| NCT02805894 NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | Prostate Cancer | P1P2 | Terminated | 5 | Open-label | NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT |
| NCT02721056 NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers | Liver Cancer | P1P2 | Terminated | 23 | Open-label | — |
| NCT01433068 NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity | Adult Soft Tissue Sarcoma | P1 | Completed | 22 | Open-label | — |
| NCT01946867 NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx | Head and Neck Cancer | N/A | Unknown | 75 | Open-label | — |